MLN 519

Drug Profile

MLN 519

Alternative Names: LDP 519; MLN519; PN 05; PS 519

Latest Information Update: 29 Jun 2006

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Class Anti-inflammatories; Lactones
  • Mechanism of Action Immunomodulators; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammation; Reperfusion injury; Stroke

Most Recent Events

  • 31 May 2004 A preclinical study has been added to the Neurological pharmacodynamics section
  • 17 Dec 2003 Preclinical data from a media release have been added to the Neurological disorders pharmacodynamics section
  • 17 Mar 2003 PAION has terminated its licence for MLN 519 in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top